Tocilizumab is an IL-6 receptor antibody that can inhibit the expression of S100A12 and NLRP3, reduce the levels of pro-inflammatory factors, such as IL-6 and TNF-α; regulate the levels of superoxide dismutase (SOD) and MDA; reduce inflammation, oxidative stress, and apoptosis in CLP mice; and improve acute lung injury caused by sepsis [66]. Here, NLRP3 is linked to Sepsis.